Table 2.
Characteristics according to BSA, BW, and BMI
| Characteristic | BSA (m2), n (%) | p* | BW (kg), n (%) | p* | BMI (kg/m2), n (%) | p* | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ≥1.48 | <1.48 | ≥53 | <53 | <18.5 | 18.5–25 | ≥25 | ||||
| Sex | ||||||||||
| Male | 29 (80.6) | 7 (19.4) | <0.0001 | 28 (77.8) | 8 (22.2) | 0.0002 | 3 (8.3) | 24 (66.7) | 9 (25.0) | 0.28 |
| Female | 40 (39.2) | 62 (60.8) | 43 (42.2) | 59 (57.8) | 20 (19.6) | 58 (56.9) | 24 (23.5) | |||
| Age (years) | ||||||||||
| <75 | 46 (63.9) | 26 (36.1) | 0.0007 | 44 (61.1) | 28 (38.9) | 0.017 | 11 (15.3) | 43 (59.7) | 18 (25.0) | 0.88 |
| ≥75 | 23 (34.8) | 43 (65.2) | 27 (40.9) | 39 (59.1) | 12 (18.2) | 39 (59.1) | 15 (22.7) | |||
| PS | ||||||||||
| 0–1 | 56 (51.8) | 52 (48.2) | 0.40 | 58 (53.7) | 50 (46.3) | 0.31 | 14 (12.9) | 68 (63.0) | 26 (24.1) | 0.07 |
| 2–4 | 13 (43.3) | 17 (56.7) | 13 (51.5) | 17 (48.5) | 9 (30.0) | 14 (46.7) | 7 (23.3) | |||
| Clinical stage | ||||||||||
| IIIB | 4 (40.0) | 6 (60.0) | 0.51 | 5 (50.0) | 5 (50.0) | 0.92 | 2 (20.0) | 6 (60.0) | 2 (20.0) | 0.93 |
| IV or rec | 65 (50.8) | 63 (49.2) | 66 (51.6) | 62 (48.4) | 21 (16.4) | 76 (59.4) | 31 (24.2) | |||
| Smoking history | ||||||||||
| Current or former | 27 (75.0) | 9 (25.0) | 0.0005 | 26 (72.2) | 10 (27.8) | 0.003 | 4 (11.1) | 23 (63.9) | 9 (25.0) | 0.57 |
| Never | 42 (41.2) | 60 (58.8) | 45 (44.1) | 57 (55.9) | 19 (18.6) | 59 (57.9) | 24 (23.5) | |||
| EGFR mutation | ||||||||||
| Exon 19 deletion | 34 (51.5) | 32 (48.5) | 0.73 | 38 (57.6) | 28 (42.4) | 0.16 | 8 (12.1) | 44 (66.7) | 14 (21.2) | 0.21 |
| Exon 21 L858R | 35 (48.6) | 37 (51.4) | 33 (45.8) | 39 (54.2) | 15 (20.8) | 38 (52.8) | 19 (26.4) | |||
Performance status was determined using the Eastern Cooperative Oncology Group criteria
BSA body surface area, BW body weight, BMI body mass index, PS performance status, EGFR epidermal growth factor receptor
*Fisher’s exact test. Italic p values are statistically significant (p < 0.05)